Owens & Minor $200 million follow-on offering
Davis Polk advised the joint book-running managers and representatives to the underwriters in connection with the approximately $200 million follow-on public offering of…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Hologic $950 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…
American Well strategic partnership with Google Cloud
Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…
BioNTech $511.5 million share offering and rights offering
Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…
Atara Biotherapeutics $175 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…
AtriCure $201.2 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…
DexCom $1.05 billion convertible notes offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…
NanoString Technologies $230 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
Based in…